Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maya Kansara

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Cancer Research|November 4, 2005
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug developmentCarleen Cullinane, Donna S Dorow, Maya Kansara, et al.
NPJ Precision Oncology|June 24, 2021
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologyFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
The Oncologist|December 25, 2024
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profilingSubotheni Thavaneswaran, Hao-Wen Sim, John Grady, et al.
Sarcoma|March 28, 2013
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma CellsJason E Cain, Andrew McCaw, W Samantha N Jayasekara, et al.
JTO Clinical and Research Reports|June 15, 2026
Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell CarcinomaPeey-Sei Kok, Bryan Chan, Mason Aberoumoud, et al.
Cancer Discovery|September 19, 2019
Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23Maya Kansara, Kristian Thomson, Puiyi Pang, et al.
The Journal of Clinical Investigation|March 25, 2009
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in miceMaya Kansara, Michael Tsang, Laurent Kodjabachian, et al.
NPJ Precision Oncology|November 21, 2025
A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burdenSubotheni Thavaneswaran, Frank Lin, David Espinoza, et al.
The American Journal of Pathology|June 24, 2005
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaBTeresa Morgan, Gerald J Atkins, Melanie K Trivett, et al.
Molecular Oncology|November 25, 2022
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumabMaya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Cancer Research|November 4, 2005
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug developmentCarleen Cullinane, Donna S Dorow, Maya Kansara, et al.
NPJ Precision Oncology|June 24, 2021
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologyFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
The Oncologist|December 25, 2024
A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profilingSubotheni Thavaneswaran, Hao-Wen Sim, John Grady, et al.
Sarcoma|March 28, 2013
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma CellsJason E Cain, Andrew McCaw, W Samantha N Jayasekara, et al.
JTO Clinical and Research Reports|June 15, 2026
Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell CarcinomaPeey-Sei Kok, Bryan Chan, Mason Aberoumoud, et al.
Cancer Discovery|September 19, 2019
Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23Maya Kansara, Kristian Thomson, Puiyi Pang, et al.
The Journal of Clinical Investigation|March 25, 2009
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in miceMaya Kansara, Michael Tsang, Laurent Kodjabachian, et al.
NPJ Precision Oncology|November 21, 2025
A signal-seeking phase 2 study of tremelimumab in advanced cancers with high tumour mutational burdenSubotheni Thavaneswaran, Frank Lin, David Espinoza, et al.
The American Journal of Pathology|June 24, 2005
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaBTeresa Morgan, Gerald J Atkins, Melanie K Trivett, et al.
Molecular Oncology|November 25, 2022
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumabMaya Kansara, Neeru Bhardwaj, Subotheni Thavaneswaran, et al.
Pageof 3